HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Unilever

This article was originally published in The Rose Sheet

Executive Summary

Dove and Axe marketer unveils consumer Web site this month on antiperspirant safety in response to reports linking the products to breast cancer, firm says. Site, which can be accessed at 1www.antiperspirantsinfo.com or 2www.deodorantinfo.com, features expert opinions from physicians, frequently asked questions and links to further information. Internet rumors in 2002 raised concerns over antiperspirant safety, but a study published in the Journal of the National Cancer Institute the same year demonstrated no link between antiperspirants and cancer (3"The Rose Sheet" Oct. 21, 2002, In Brief)...

You may also be interested in...



Antiperspirants and cancer

Use of antiperspirants or deodorants was not linked to an increased risk of breast cancer in a population-based case-control study published in the Oct. 16 Journal of the National Cancer Institute. Conducted by Dana Mirick, Fred Hutchinson Cancer Research Center, Seattle, et al., study involved 810 women diagnosed with breast cancer, 793 controls who were interviewed about antiperspirant and deodorant use following underarm hair removal. "To our knowledge," researchers state, "this is the only epidemiologic evidence pertaining to a possible association" between antiperspirants/deodorants and breast cancer and "our results provide no indication that such a relationship exists." Study prompted by "persistent" Internet rumors of a connection between the products and cancer...

Biogen Sees Improving Momentum In Slow Leqembi Launch

Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.

Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease

Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS012693

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel